NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China.
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510515, People's Republic of China.
Biomaterials. 2022 Apr;283:121449. doi: 10.1016/j.biomaterials.2022.121449. Epub 2022 Mar 1.
Designing and developing nanomedicine based on the tumor microenvironment (TME) for effective cancer treatment is highly desirable. In this work, polyvinyl pyrrolidone (PVP) dispersed nanoscale metal-organic framework (NMOF) of Fe-TCPP (TCPP = tetrakis (4-carboxyphenyl) porphyrin) loaded with hypoxia-activable prodrug tirapazamine (TPZ) and coated by the cancer cell membrane (CM) is constructed (the formed nanocomposite denoted as PFTT@CM). Due to the functionalization with the homologous cancer cell membrane, PFTT@CM is camouflaged to evade the immune clearance and preferentially accumulates at the tumor site. Once internalized by cancer cells, PFTT@CM is activated by the TME through redox reaction and Fenton reaction between Fe in nano-platform and endogenous glutathione (GSH) and hydrogen peroxide (HO) to promote GSH exhausting as well as •OH and O production, which triggers ferroptosis and dramatically enhances photodynamic therapy (PDT) efficacy. Subsequently, the PDT process mediated by TCPP and light would consume oxygen and aggravate tumor hypoxia to further activate the prodrug TPZ for cancer chemotherapy. As a consequence, the TME-driven PFTT@CM nano-platform not only demonstrated its TME modulation ability but also showed a sequential synergistic therapy, which eventually inhibited the cancer cell proliferation. This multimodal nano-platform is expected to shed light on the design of TME-activatable reaction to reinforce the synergistic therapeutic outcome and facilitate the development of effective cancer nanomedicine.
基于肿瘤微环境(TME)设计和开发用于有效癌症治疗的纳米医学是非常可取的。在这项工作中,构建了负载缺氧激活前药替拉扎胺(TPZ)并包覆癌细胞膜(CM)的聚维酮(PVP)分散的纳米级金属有机骨架(NMOF)的 Fe-TCPP(TCPP=四(4-羧基苯基)卟啉)(形成的纳米复合物表示为 PFTT@CM)。由于与同源癌细胞膜的功能化,PFTT@CM 被伪装以逃避免疫清除,并优先积聚在肿瘤部位。一旦被癌细胞内化,PFTT@CM 通过纳米平台中的 Fe 与内源性谷胱甘肽(GSH)和过氧化氢(HO)之间的氧化还原反应和芬顿反应在 TME 中被激活,以促进 GSH 耗尽以及•OH 和 O 的产生,从而引发铁死亡并显著增强光动力疗法(PDT)效果。随后,TCPP 和光介导的 PDT 过程会消耗氧气并加重肿瘤缺氧,从而进一步激活用于癌症化疗的前药 TPZ。因此,TME 驱动的 PFTT@CM 纳米平台不仅表现出其 TME 调节能力,而且还表现出顺序协同治疗,最终抑制了癌细胞增殖。这种多模式纳米平台有望为设计 TME 激活反应提供启示,以增强协同治疗效果,并促进有效的癌症纳米医学的发展。